Loisance D, Dubois Rande J L, Deleuze P H, Hillion M L, Duval A M, Tavolaro O, Romano P, Castaigne A, Tarral A, Cachera J P
Department of Cardiac Surgery, C.H.U. Henri Mondor, Créteil, France.
Eur J Cardiothorac Surg. 1989;3(3):196-202. doi: 10.1016/1010-7940(89)90066-3.
From September 1985 to August 1988, 32 patients were referred from various intensive care units throughout Paris for urgent cardiac transplantation or for a mechanical bridge to transplantation. At time of admission, under maximal sympathomimetic therapy, the cardiac index (CI) was 1.81 +/- 0.26 l/min per m2, the pulmonary capillary wedge pressure (PCWP 31 +/- 7 mmHg), systemic vascular resistances (SVR) 2053 +/- 469 dynes s cm-5. In 25, diuresis was less than 25 ml/h. Five were anuric. Prior to any final decision, a new inotropic agent, enoximone, was infused in addition to previous treatment as a 10 min bolus iv 1.5-2 mg/kg every 8 h. In 3, the situation further deteriorated, leading to a Jarvik 7-70 implantation within 12 h. In 29 however, within 3 h, the Cl increased to 2.69 +/- 0.56 as SVR dropped to 1410 +/- 453 and PCWP to 18 +/- 7. Diuresis increased to more than 100 ml/h in all. This permitted an indepth evaluation of the transplant candidates leading to contraindications to transplantation in 16. Nine patients could be weaned off iv enoximone. Four of these are still living (NYHA class III) with a follow up of 6-17 months. In 11, transplantation was performed within 2 days. Four died within a month, 2 with multiple organ failure. One patient died after 5 months. Six are back to normal life, NYHA class I (follow up 10 months-2.5 years). This protocol suggests that in patients with extreme heart failure, immediate survival may be increased by iv enoximone therapy, permitting a better selection of the recipients, more efficient pre-transplantation intensive care and consequently a decrease in the indications for a temporary mechanical bridge to a staged transplantation.
1985年9月至1988年8月,来自巴黎各地重症监护病房的32例患者被转诊接受紧急心脏移植或作为移植的机械过渡手段。入院时,在最大剂量拟交感神经药物治疗下,心脏指数(CI)为1.81±0.26升/分钟每平方米,肺毛细血管楔压(PCWP)为31±7毫米汞柱,全身血管阻力(SVR)为2053±469达因·秒·厘米⁻⁵。25例患者的尿量少于25毫升/小时。5例无尿。在做出任何最终决定之前,除先前治疗外,一种新的强心剂依诺昔酮以1.5 - 2毫克/千克的剂量每8小时静脉推注10分钟。3例患者病情进一步恶化,在12小时内接受了Jarvik 7 - 70植入。然而,在29例患者中,3小时内CI增加到2.69±0.56,SVR降至1410±453,PCWP降至18±7。所有患者的尿量均增加到超过100毫升/小时。这使得能够对移植候选者进行深入评估,导致16例患者出现移植禁忌证。9例患者可以停用静脉注射依诺昔酮。其中4例仍存活(纽约心脏协会III级),随访6 - 17个月。11例患者在2天内接受了移植。4例在1个月内死亡,2例死于多器官功能衰竭。1例患者在5个月后死亡。6例恢复正常生活,纽约心脏协会I级(随访10个月 - 2.5年)。该方案表明,对于极度心力衰竭患者,静脉注射依诺昔酮治疗可能会提高即刻生存率,从而更好地选择受者,更有效地进行移植前重症监护,进而减少分期移植临时机械过渡的指征。